For instance, the consumption of specific nutrients and the engagement in regular physical activity have been identified as key contributors to optimizing GLP-1 secretion
Individuals at risk of AD or with diabetes may be in the early or middle biological stage of AD, offering a greater opportunity for GLP-1RAs to provide neuroprotection
Bottom Line Here's what the data tells us: GI side effects dominate: nausea, diarrhea, vomiting, constipation Higher efficacy = slightly higher side effects at maximum doses Glucagon adds benefits: liver fat reduction, increased energy expenditure Slow escalation helps: 20+ week titration minimizes symptoms Still investigational: Phase 3 trials ongoing, FDA decision expected 2025-2026 Sources Retatrutide Phase 2 Trial (Jastreboff et al., NEJM 2023) TRIUMPH Phase 3 Trial (ClinicalTrials.gov) ClinicalTrials.gov Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice
If youre suffering from symptoms already, you may notice some benefits more than others
This treatment is often recommended for patients managing obesity or excess weight, especially when weight-related conditions such as high blood pressure, diabetes, or metabolic issues are also present
Others are more flexible